

April 7, 2025

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sirs,

Sub: Appointment of Senior Management Personnel of the Company

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), the Board on the recommendation of Nomination Remuneration Committee, vide Circular resolution dated April 6, 2025, has appointed Mr. Anurag Mantri as President (Senior Management Personnel) with effect from April 7, 2025.

Further, we have to inform you that, Mr. V.S. Mani, Executive Director & Global Chief Financial Officer of the Company has conveyed his decision to opt for early retirement and has decided to step down from the position of Executive Director and Global Chief Financial Officer with effect from close of May 26, 2025. Although, for smooth transition, he has agreed to continue with the Company for some time.

The candidature of Mr. Anurag Mantri to the office of Executive Director & Global Chief Financial Officer will be put up before Audit Committee, Nomination & Remuneration Committee and Board of the Company in the ensuing committee meetings/Board meeting for approval and once approved, he will then be appointed as Executive Director and Global Chief Financial Officer.

The details of the aforesaid appointment and resignation as prescribed under SEBI Listing Regulations read with SEBI circular SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023, is enclosed as Annexure A.

The copy of the resignation letter as received from Mr. V.S. Mani is enclosed as Annexure B.

You are requested to take the same on record.

Thanking You.

Yours faithfully,

For Glenmark Pharmaceuticals Limited

Harish Kuber

Company Secretary & Compliance Officer

Encl: As above

Glenmark Pharmaceuticals Limited

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

Annexure A

Disclosure of events and information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023

S. No.	Particulars	Details	
1.	Name	Mr. Anurag Mantri	Mr. V.S. Mani
2.	Reason for change	Appointment	Resignation
3.	Date of term of appointment	April 7, 2025	Not Applicable
4.	Brief Profile	Anurag Mantri is joining from Jindal Stainless Limited where he served as Executive Director & Group Chief Finance Officer since 2016. Anurag has over thirty years of management experience where he has led large scale enterprise value creation, managed large IPO's and global compliance, mergers and acquisitions, corporate finance. He has also had roles of increasing responsibility in treasury, IR, tax and ERP deployment. Anurag began his career with Larsen & Toubro as part of their Corporate Finance & Group Treasury team. Subsequently he had impactful stints with HCL Technologies as Corporate Treasurer and SRF Limited as Head treasury, Investor Relations and Mergers & Acquisitions respectively. Post which he spent six years with Cairn Energy as their Group Treasurer & Financial Controller and Head Investor Relations. After this Anurag joined ACME Group (Solar) briefly as their Executive Director, Finance and Strategy & Group Chief Financial Officer before joining Schneider Electric Infrastructure Limited (SEIL) as Chief Financial Officer. He is a qualified chartered accountant and a Bachelor in Commerce from the University of Rajasthan.	Not Applicable
5.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable	Not Applicable

Glenmark Pharmaceuticals Limited

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

April 6, 2025

To
The Board of Directors,
Glenmark Pharmaceuticals Limited
Glenmark House,
B. D. Sawant Marg,
Off. Western Express Highway,
Mumbai - 400 099

Dear Madam / Sir,

Sub.: Early retirement from the position of Executive Director & Global Chief Financial Officer of Glenmark Pharmaceuticals Limited ("the Company")

After an enriching journey of about eight years with the Company, and considering that I have crossed 60 years of age and have decided to take early retirement. I have decided to step down from my position as Executive Director & Global Chief Financial Officer. Accordingly, I hereby submit my resignation, with effect from close of May 26, 2025. For smooth transition I am willing to continue in the employment of the Company for some time.

I am deeply grateful for the unwavering support of Mr. Glenn Saldanha, the Chairman & Managing Director, fellow Board members, my peers, my team and all other colleagues in the organization whose dedication and vision have been instrumental in shaping the Company's success.

Request you to kindly take this on record and initiate necessary steps for filing the intimation with necessary authorities.

As I move forward, I extend my best wishes to Glenmark for its continued growth and prosperity.

Thanking you,



V.S. Mani
DIN: 01082878